Lilly’s $7bn acquisition of Kelonia seems to be bearing fruit, with other in vivo approaches showing promise.
In vivo CAR T therapies are starting to show promise in data released at ASCO 2026. Credit: Nemes Laszlo / Shutterstock.com
As the American Society for Clinical Oncology (ASCO) meeting of 2026 has drawn to a close, experts are still sifting through the mountain of data presented at the conference.
Among that is data on novel cell therapy approaches, including in vivo cell therapies, which are showing promise in blood and skin cancer. Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
